Related by context. All words. (Click for frequent words.) 72 methodological shortcomings 71 methodologic 70 methodological flaws 69 methodological weaknesses 65 randomized controlled trials RCTs 65 neuropsychological impairments 65 unmeasured confounders 64 Subgroup analyzes 64 residual confounding 63 neuropsychiatric symptoms 63 underdiagnosis 63 Meta analyzes 62 subgroup analyzes 62 unmeasured factors 62 generalisability 62 meta analyzes 62 RCTs 61 nonrandomized studies 61 metaanalysis 61 diagnosing ADHD 61 correlational 61 postmarketing surveillance 61 methodologically sound 61 Multiple logistic regression 61 generalizability 61 ConclusionThis 60 VADT 60 Observational studies 60 epidemiologic studies 60 follicular adenoma 60 STEP BD 60 Cognitive impairment 60 vitamin D inadequacy 59 testosterone supplementation 59 Longitudinal studies 59 poststroke depression 59 Cochrane reviewers 59 selenium supplementation 59 psychiatric comorbidity 59 Bresalier 59 riociguat 59 radiographic findings 59 confounding variables 59 functional neuroimaging 59 non pharmacological interventions 59 nonadherence 59 Multivariable logistic regression 59 neuroimaging studies 58 PROactive study 58 methodologically rigorous 58 oncologic outcomes 58 underlying molecular mechanisms 58 ascertainment bias 58 nonrandomized 58 biochemical abnormalities 58 atypical antipsychotic medications 58 convergent validity 58 placebo controlled trials 58 pharmacological interventions 58 atypical femur fractures 58 placebo controlled studies 58 methodological differences 58 endoscopic examinations 58 causal inference 58 longitudinal cohort 58 alexithymia 58 clinically insignificant 58 Genetic predisposition 58 topical NSAIDs 58 meta regression 58 artifactual 58 reboxetine 57 nonpharmacologic 57 psychiatric comorbidities 57 methodological rigor 57 observational studies 57 Multivariate logistic regression 57 Hepatotoxicity 57 MERLIN TIMI 57 pharmacokinetic interactions 57 prostate carcinogenesis 57 pharmacologic treatments 57 intensive statin therapy 57 cognitive behavioral therapies 57 β blockers 57 predictive validity 57 methodological 57 etiological factors 57 thiopurine 57 meta analytic 57 Multivariate analyzes 57 Rigorous scientific 57 comorbid conditions 57 retrospective observational 57 familial clustering 57 perioperative morbidity 57 neuropsychiatric events 56 hypochondriasis 56 pathologic fractures 56 pharmacoeconomic 56 cerebral microbleeds 56 chemoprevention trials 56 stone formers 56 postmarketing adverse 56 psychotherapies 56 conventional angiography 56 chromosomal rearrangement 56 undiagnosed celiac disease 56 causal inferences 56 spirometric 56 statin medications 56 prospective observational studies 56 testicular dysgenesis syndrome 56 myopathy rhabdomyolysis 56 IQWiG 56 underlying pathophysiology 56 newer atypical antipsychotics 56 neurologic abnormalities 56 adjuvant therapies 56 spontaneous regression 56 impaired insulin secretion 56 Prof. Krainer 56 ALLHAT 56 Randomized trials 56 androgen deficiency 56 incidentalomas 56 vasogenic edema 56 body habitus 56 postmenopausal hormones 56 probiotic supplementation 56 renal toxicity 56 randomized controlled clinical trials 56 neurosensory 56 multicenter trials 56 SpHb monitoring 55 undiagnosed untreated 55 Epidemiologic studies 55 hamartomas 55 biologic plausibility 55 CPAP adherence 55 recurrent headaches 55 BRCA testing 55 psychopharmacological 55 Subgroup analysis 55 varicoceles 55 pathogenetic mechanisms 55 neurocognitive deficits 55 neurocognitive functioning 55 neuropsychological assessment 55 aldosterone antagonist 55 delayed gastric emptying 55 psychopathological symptoms 55 neurocognitive impairment 55 pure fructose 55 radiographic outcomes 55 generalisable 55 psychosocial stressors 55 MGUS 55 ACCORD Lipid 55 colorectal neoplasia 55 Nissen meta analysis 55 asymptomatic PAD 55 subclinical disease 55 immunological responses 55 PRIMO CABG 55 intravenous bisphosphonates 55 familial aggregation 55 EMPOWER TM 55 dose proportionality 55 Chronic Lyme disease 55 neuropsychological impairment 55 Systematic reviews 55 antioxidant supplementation 55 IMPROVE HF 55 dopaminergic therapy 55 impair fertility 55 COIs 55 randomized trials 55 etiological 55 logistic regression analyzes 55 postmarket surveillance 55 Non inferiority 55 methotrexate therapy 55 parkinsonian symptoms 55 postmenopausal hormone therapy 55 preoperative diagnosis 55 inactivated influenza vaccines 55 antibiotic rifaximin 55 somatic mutations 55 somatoform disorders 55 anticholinergic drugs 55 hypersensitivity allergic reactions 55 developmental neurotoxicity 55 non selective NSAIDs 55 maximal doses 55 BEXXAR therapeutic regimen 55 somatic symptoms 55 periprocedural MI 55 compulsive hoarding syndrome 55 lipid lowering therapy 54 PDE 5i 54 PLCO trial 54 hypoglycemic episodes 54 unipolar depression 54 neurologic symptoms 54 adrenal suppression 54 orofacial clefts 54 androgen excess 54 carotid stenosis 54 STICH trial 54 bronchopulmonary dysplasia BPD 54 premorbid 54 Dr. Relkin 54 QT prolongation 54 QTc prolongation 54 DHEA supplementation 54 mtDNA mutations 54 prognostically 54 intracranial stenosis 54 microscopic hematuria 54 comorbid disorders 54 interobserver 54 XMRV infection 54 conditional logistic regression 54 genomewide association studies 54 somatoform disorder 54 journal Ophthalmology 54 androgen depletion therapy 54 nongenetic 54 APOE genotype 54 genotypic resistance 54 antibiotic regimens 54 mammographically 54 psychodynamic therapy 54 recurrent miscarriage 54 Dr. Fombonne 54 neurophysiologic 54 oral NSAIDs 54 Fanconi syndrome 54 CTEPH 54 preoperative MRI 54 thromboprophylaxis 54 chromium picolinate supplementation 54 Shlipak 54 meta analysis pooling 54 bivariate analyzes 54 pharmacological therapies 54 autonomic dysfunction 54 Dr. Roehrborn 54 abnormal glucose tolerance 54 atherogenic dyslipidemia 54 journal CHEST 54 interindividual variability 54 confounder 54 perioperative complications 54 mitochondrial toxicity 54 hematopoietic cancers 54 Kaplan Meier curve 54 COX 2s 54 journal Neuropsychology 54 extracolonic findings 54 hepatotoxicity 54 APPROVe trial 54 Zevalin consolidation 54 ecotoxicological 54 GnRH agonists 54 viral etiology 54 neuropsychological deficits 54 antiepileptics 54 coronary calcification 54 cardiac toxicity 54 etiologic 54 SNP rs# [002] 54 teratogenicity 54 beta carotene supplementation 54 Bonferroni correction 54 prospective longitudinal 54 LVNC 54 fetal malformations 54 phytoestrogen intake 54 prognostic indicators 54 CLBP 54 perinatal outcomes 54 neurodevelopmental outcome 53 unmeasured confounding 53 KIF6 carriers 53 therapeutic regimens 53 coinfected patients 53 intraobserver 53 mechanistic studies 53 endoscopists 53 chlamydial infection 53 semistructured interviews 53 neurologic complications 53 oncological outcomes 53 differential gene expression 53 STRIDE PD 53 postapproval 53 myocardial dysfunction 53 developmental trajectories 53 cardioprotective effect 53 ACOSOG Z# 53 NATRECOR ® 53 angiographically 53 noscapine 53 EEG abnormalities 53 CYP #A# 53 Hurthle cell 53 DCIS lesions 53 loop diuretics 53 #F FDG PET 53 Multiple linear regression 53 bile acid metabolism 53 differential diagnoses 53 pyridostigmine 53 inferential statistics 53 anecdotal observations 53 symptomatic paroxysmal AF 53 aetiological 53 atypical fractures 53 scintigraphic 53 NP CRNs 53 diabetic polyneuropathy 53 newer antipsychotics 53 postexposure prophylaxis 53 SGAs 53 CAM modalities 53 pulmonary toxicity 53 UKPDS 53 multivariate adjustment 53 acetabular fractures 53 neuropathologic 53 infantile amnesia 53 primary aldosteronism 53 elevated bilirubin 53 congenital malformations 53 depressive illnesses 53 prospective multicentre 53 herpes zoster vaccine 53 venous thromboembolism prophylaxis 53 Nanette Wenger 53 neurological abnormalities 53 Randomized clinical trials 53 renal biopsy 53 routine episiotomy 53 NNRTI resistance 53 statins cholesterol lowering 53 toxicologic 53 anatomical abnormalities 53 #q# deletion 53 trials RCTs 53 genotype phenotype 53 clefting 53 OAB symptoms 53 VCUG 53 vascular dysfunction 53 epidemiological studies 53 masitinib 53 silent myocardial ischemia 53 morphometric vertebral fractures 53 PDE4 inhibitors 53 hepatic toxicity 53 hsCRP levels 53 Randomised controlled trials 53 KRAS status 53 serotonin deficiency 53 pharmacokinetic interaction 53 chronic LBP 53 malignant polyps 53 randomized controlled trials 53 glitazones 53 subconjunctival hemorrhage 53 teratogenic 53 deferiprone 53 plasma pharmacokinetics 53 Dickersin 53 lung cancer NSCLC 53 GBA mutations 53 Dose adjustments 53 supine hypertension 53 retrospective cohort 53 Deutsches Arzteblatt International 53 Suicidal tendencies 53 empirically validated 53 APOE ε4 53 genomic biomarker 53 antiplatelet therapies 53 neurodevelopmental outcomes 53 limiting generalizability 53 stratifying patients 53 Dr. Chenchen Wang 53 multivariate analyzes 53 psychotherapeutic interventions 53 airway responsiveness 53 cardiac malformations 53 pharmacologic interventions 53 multisymptom illness 52 newer antipsychotic medications 52 BUSM researchers 52 paroxetine Seroxat 52 beta blocker therapy 52 pharmacological therapy 52 placebo controlled clinical trials 52 familial predisposition 52 histopathological examination 52 TNF blocker therapy 52 OSAHS 52 thiazide 52 behavioral abnormalities 52 chronic prostatitis chronic 52 pathologic examination 52 histologic examination 52 intracerebral haemorrhage 52 logistic regression models 52 NICE SUGAR 52 Dr. Cerhan 52 prognostic variables 52 exploratory endpoints 52 VIGOR study 52 CLA supplementation 52 mechanistic insights 52 overactive bladder symptoms 52 pharmacokinetic characteristics 52 Clinical Antipsychotic Trials 52 PREVENT IV 52 mitochondrial metabolism 52 IV bisphosphonates 52 de novo mutations 52 extrapyramidal symptoms 52 Math LD 52 Vitamin B# deficiency 52 acid suppressive drugs 52 antenatal depression 52 anatomic abnormalities 52 chest radiographs 52 plain radiographs 52 sonographic findings 52 carotid IMT 52 SLNB 52 Heritability 52 BARI 2D 52 clinicopathological 52 biological plausibility 52 pharmacodynamic parameters 52 AChE inhibitors 52 hypercoagulable 52 prophylactic cranial irradiation 52 HAART regimens 52 TNF antagonist 52 Dr. Yolton 52 covariate 52 liver transaminases 52 premenopause 52 TMPRSS2 ERG fusion 52 HIV tropism 52 azoospermia 52 journal Pharmacoepidemiology 52 empiric 52 Dr. Chodick 52 gonococcal 52 phthalate exposure 52 intestinal biopsy 52 AVERROES 52 guideline concordant 52 histopathological 52 adjuvant systemic 52 brain lesions 52 reflux symptoms 52 Torsades de Pointes 52 Human Reproduction journal 52 androgen depletion 52 elevated ALT 52 physico chemical properties 52 NSQIP 52 etiologies 52 perceptual biases 52 antiplatelet drugs 52 subclinical atherosclerosis 52 WHEL 52 Intervention Effectiveness CATIE 52 stem cell transplantations 52 Mechanistic studies 52 structural lineaments 52 endocrinologic 52 Personality disorders 52 comorbid diagnoses 52 BRCA gene mutations 52 HIV HCV coinfected 52 PLCO 52 diagnosing bipolar disorder 52 lipid abnormalities 52 EoE 52 hematologic parameters 52 coexisting illnesses 52 psychosocial variables 52 sacral neuromodulation 52 DMIST 52 Pathological gambling 52 subclinical cardiovascular disease 52 EUS FNA 52 atherothrombotic 52 lipid lowering medications 52 syndromal 52 CARE HF 52 prodromal symptoms 52 cardioembolic stroke 52 prenatal exposures 52 comorbid illnesses 52 tumor histology 52 perfusion CT 52 lipid lowering agents 52 Polygraph examinations 52 thyrotropin levels 52 urodynamic studies 52 randomized clinical trials 52 RE LY trial 52 bibliometrics 52 anticholinergic effects 52 Serious adverse reactions 52 periodontal infections 52 ADAGIO study 52 urolithiasis 52 statistical correlations 52 liver toxicity 52 meniscal damage 52 comorbid psychiatric disorders 52 methodologically flawed 52 symptomology 52 Alan Dangour 52 Intervention Trial GAIT 52 prospective nonrandomized 52 autistic traits 52 myocardial ischaemia 52 QT interval prolongation 52 atherothrombotic disease 52 genetic susceptibilities 52 bezafibrate 52 depressive symptomatology 52 psychiatric morbidity 52 schizotypal traits 52 subthreshold depression 52 Leitzmann 52 behavioral disinhibition 52 infantile colic 52 Thyroid nodules 52 thorough QT 52 arzoxifene 52 psychobiological 51 subclinical hyperthyroidism 51 postmarketing 51 genetic loci 51 behavioral disturbances 51 ACCORD Eye 51 ß blockers 51 FDG PET imaging 51 swallowing disorders 51 ECG abnormalities 51 CT perfusion 51 perseverative 51 nonpsychiatric 51 heritable variation 51 typical antipsychotics 51 antidepressant efficacy 51 cardiac repolarization 51 cranial irradiation 51 Singh Manoux 51 oseltamivir resistance 51 immunohistochemical 51 comorbid depression 51 postoperative atrial fibrillation 51 histologic diagnosis 51 ziconotide 51 acetabular dysplasia 51 metabolic derangement 51 carotid artery stenosis 51 histologic subtypes 51 dose statin therapy 51 chromosomal anomalies 51 MDRD equation 51 dyslipidaemia 51 DHA supplementation 51 hematopoietic malignancies 51 HRQL 51 comorbidities 51 Excessive daytime sleepiness 51 multiple linear regression 51 fluoxetine Prozac 51 functional gastrointestinal disorders 51 transaminase elevations 51 linear pharmacokinetics 51 hyperactivity inattention 51 uncharacterized genes 51 attain statistical significance 51 thyroid dysfunction 51 genomic alterations 51 BEXXAR Therapeutic Regimen 51 subclinical hypothyroidism 51 urine cytology 51 Sociodemographic 51 syncopal episode 51 untreated hypothyroidism 51 urinary incontinence UI 51 microdeletion 51 serum biomarkers 51 carotid plaque 51 Personality traits 51 immunosuppressive agents 51 poor metabolizers 51 nomograms 51 Redei 51 dietary antioxidants 51 CARDIA study 51 nonclinical studies 51 cortical atrophy 51 colorectal carcinogenesis 51 phase IIIb 51 monogenic 51 Dr. Cliby 51 Screening Trial DMIST 51 glucose abnormalities 51 FDA Adverse Event 51 paroxysmal AF 51 imatinib therapy 51 Dose escalation 51 apneic episodes 51 primary dysmenorrhoea 51 Dr. Fonstein 51 Multivariate analysis 51 beta carotene supplements 51 econometric analyzes 51 longitudinal studies 51 concomitant medications 51 contraindicate 51 CSF biomarkers 51 Relapsing remitting MS 51 carotid plaques 51 sotalol 51 untreated OSA 51 androgen suppression 51 S. maltophilia 51 unintentional ingestion 51 Alequel 51 amenorrhoea 51 hematological toxicity 51 echogenic foci 51 methodologically 51 COX inhibitors 51 clinico pathological 51 immune suppressing medications 51 colorectal liver metastases 51 thromboembolism 51 haematological 51 PNH patients 51 microvascular disease 51 EBUS FNA 51 dietary interventions 51 Szeinbach 51 GFT# 51 SCK difficulty 51 molecular determinants 51 INTERHEART study 51 nutrient supplementation 51 PCPT 51 stepwise logistic regression 51 sideeffects 51 Sackner Bernstein 51 Cinzia Marano 51 Cochrane Systematic Review 51 postoperative chemotherapy 51 histopathologic 51 noncognitive 51 NHAMCS 51 statistically significant correlations 51 empiric therapy 51 aminotransferases 51 multivariate logistic regression 51 G. biloba 51 sCJD 51 clomipramine 51 APEX AMI trial 51 amisulpride 51 Nesiritide 51 fi ndings 51 prostate cancer CaP 51 MMP inhibitors 51 F FDG PET 51 internalizing behaviors 51 surrogate markers 51 impaired cognition 51 Avandia Actos 51 clinically meaningful differences 51 macrovascular disease 51 pleiotropy 51 carotid artery narrowing 51 allogeneic HSCT 51 SORT OUT III 51 perfusion abnormalities 51 inhaled glucocorticoids 51 embryo biopsy 51 journal Resuscitation 51 pleiotropic effects 51 metabolite concentrations 51 intracranial hemorrhage ICH 51 tardive dyskinesia TD 51 FDG PET scans 51 optic neuropathy NAION 51 bovine thrombin 51 pharmacological approaches 51 Symptom severity 51 sleep apneas 51 mucinous 51 lowering homocysteine 51 AMOR IPAT 51 liver biopsies 51 unconscious biases 51 meningiomas 51 immunodeficiencies 51 venous thromboembolic disease 51 intolerability 51 cerebral angiography 51 Logistic regression analysis 51 GI bleeding 51 metabolic parameters 51 toxicological studies 51 environmental toxicants 51 LC#m# vaccine 51 randomizing patients 51 Stent thrombosis 51 uridine triacetate 51 oral antidiabetes drugs 51 emotional dysregulation 51 warfarin dosing 51 renal artery stenosis 51 gemifloxacin 51 pressor response 51 ACUITY trial 51 vitro experiments 51 percutaneous biopsy 51 nonmelanoma skin cancers 51 myocardial infarctions 51 G6PD deficiency 51 Sirovich 51 neuroleptics 51 fluoroquinolone resistance 51 mania hypomania 51 Kadan Lottick 51 EDEMA3 trial 51 REACH Registry 51 PRIMO CABG2 51 microarray gene expression 51 BRCA carriers 51 IGRAs 51 thromboembolic 51 TEAEs 51 irregular menstrual periods 51 androgen deprivation 51 GIST tumors 51 Selective Serotonin Reuptake Inhibitor 51 schizophreniform disorder 51 lipid lowering therapies 51 Calcium intake 51 dietary acrylamide 51 memantine Namenda 51 sociologic 51 aortic regurgitation 51 MMSE scores 51 lipid lowering medication 51 implicit biases 51 percutaneous cryoablation 51 Dangour 51 cartilage degeneration 51 MDRD 51 menopausal hormone therapy 51 nonstandardized 51 multivariate regression analysis 51 psychiatric diagnoses 51 multiple logistic regression 51 preclinical pharmacokinetic 51 probabilistic reasoning 51 postprocedure 51 antiplatelet medications 51 sputum specimens 51 pathophysiological mechanisms 51 hypercholesterolemic patients 51 Schaffir 50 EGFR expression 50 symptomatic aortic stenosis 50 tricyclic anti depressants 50 SRBD 50 bone scintigraphy 50 QTc intervals 50 Epileptic seizures 50 prospectively stratified 50 XRF readings 50 calcaneal fractures 50 TRPV1 antagonists 50 #q#.# deletion syndrome 50 Serious Adverse Events 50 EMPOWER ™ 50 journal BJU International 50 biologic DMARDs 50 SCD HeFT 50 vismodegib 50 Cytogenetic 50 Epidemiological studies 50 thrombophilia 50 CT urography 50 maladaptive behaviors 50 potent antiretroviral therapy 50 corticosteroid therapy 50 nesiritide 50 intracranial hypertension 50 prognostic markers 50 CP CPPS 50 internalizing disorders 50 hypoperfusion 50 chronicity 50 thimerosal exposure 50 commonly prescribed antidepressants 50 ROCKET AF 50 antithrombotic therapy 50 undertreatment 50 imply causality 50 risperidone Risperdal 50 estrogen progestin therapy 50 PM#.# exposure 50 noncardiac 50 postoperative infections 50 follicular lymphomas 50 nosology 50 comorbidity 50 KRAS mutation 50 dosimetric 50 Heisenberg principle 50 acid suppressive therapy 50 visceral metastases 50 ICD implantations 50 advanced neoplasia 50 ACCORD ADVANCE 50 journal Pharmacotherapy 50 WARNINGS Myopathy Rhabdomyolysis 50 nonhematologic adverse reactions 50 polyarticular 50 nonfatal crashes 50 Prostatitis 50 obstetric ultrasound 50 neuroanatomical 50 acute myocardial infarction MI 50 cytologic 50 precaution Wiehle 50 thromboembolic complications 50 noncardiac chest pain 50 Wisconsin Sleep Cohort 50 nonvaccine 50 compendia 50 patently unreliable 50 eculizumab therapy 50 antiepileptic drugs 50 VaD 50 endophenotypes 50 HBV infections 50 K ras mutation 50 LV dysfunction 50 inherit predisposition 50 thyroid nodules 50 univariate analyzes 50 hormonal abnormalities 50 FDA reviewers 50 nucleotide substitutions 50 IGFD 50 overdiagnose 50 elevated CRP 50 immunohistochemical analysis 50 esophageal reflux 50 oral taxanes 50 leiomyomas 50 Hip dysplasia 50 Eunyoung Cho 50 haematologic 50 Carotid Revascularization Endarterectomy vs. 50 Wernicke Korsakoff syndrome 50 better childproof containers 50 histologic findings 50 biopsychosocial model 50 TCF#L# gene 50 Zemiva imaging 50 CYPHER R Sirolimus eluting 50 phylogenetic analyzes 50 gene APOE4 50 paternal discrepancy 50 thromboembolic disease 50 serologic testing 50 Striegel Moore 50 Society ILADS 50 Digital Mammographic Imaging 50 NAbs 50 HF ACTION 50 slow metabolizers 50 genetic polymorphism 50 postmenopausal estrogen 50 pharmacological treatments 50 obstetric complications 50 CYPHER Stent 50 Conclusive evidence 50 biopsychosocial 50 genomic deletions 50 rFVIIa 50 carcinogenicity studies 50 lymph node involvement 50 INTERHEART 50 vascular endothelial dysfunction 50 CYP#C# genotype 50 gastrointestinal GI bleeding 50 calcineurin inhibitors 50 histological examination 50 EBV infection 50 autoimmune reactions 50 magnesium supplementation 50 Methodological 50 Critical limb ischemia 50 adverse cytogenetics 50 acute phosphate nephropathy 50 sonographic appearance 50 trastuzumab emtansine T DM1 50 immunosuppressive regimens 50 DMARDS 50 genetic determinants 50 upper gastrointestinal endoscopy 50 cardioprotective effects 50 postoperative mortality 50 ischemic cardiomyopathy 50 neuropsychological evaluations 50 Telomere length 50 univariate 50 colonoscopic 50 HER2 expression 50 Dr. Tobias Kurth 50 Adverse effects 50 asymptomatic bacteriuria 50 gadobutrol 50 Myocardial ischemia 50 Achilles tendon ruptures 50 pharmacologic stress 50 clevidipine 50 chemobrain 50 Postoperative complications 50 Intermountain Risk Score 50 underestimations 50 JoAnn Manson 50 peer reviewed literature 50 HAV infection 50 surveys Herbenick 50 Myerburg 50 clinicopathologic 50 Cytolin ® 50 contralateral breast cancer 50 untreated celiac disease 50 ultrasound elastography 50 proliferative diabetic retinopathy 50 Chest x rays 50 neurologic impairment 50 antiepileptic drugs AEDs 50 antiangiogenic agents 50 fumagillin nanoparticles 50 euthymic patients 50 neuroleptic drugs 50 multifactorial 50 detect XMRV 50 Levy Lahad 50 Familial hypercholesterolemia 50 CAVEATS 50 mammographic density 50 antibiotic prophylaxis 50 Depressive symptoms 50 fight PI3K activation 50 varicella infection 50 treatment emergent AEs 50 meta analysis 50 Chlamydia trachomatis infection 50 SYNTAX trial 50 akinetic mutism 50 methodological approaches 50 physiologic mechanisms 50 Newschaffer 50 infantile hemangiomas 50 androgen ablation 50 ASCEND HF 50 number NCT# ClinicalTrials.gov 50 interobserver variability 50 liver transplant recipients 50 Comorbid 50 hip resurfacing arthroplasty 50 sonographic diagnosis 50 left ventricular dysfunction 50 causal linkage 50 Nutrient deficiencies 50 psychometric properties 50 Exclusion criteria 50 O PPDS